Objective: Equol, which is an active metabolite of isoflavone, has a beneficial impact on metabolic diseases such as dyslipidemia and hyperglycemia. However, the effect of equol on obesity remains uncertain. This study was performed to determine the association between equol and obesity in postmenopausal women.
Methods: We evaluated 386 women in their 50s-60s who underwent health check-ups from February 2018 to January 2019 at Watari Hospital Health Center in Fukushima, Japan. Overweight and visceral obesity were defined as a body mass index ≥25 kg/m2 and waist circumference ≥ 90 cm, respectively. Participants were asked to complete a questionnaire about their ordinary lifestyle. Participants were defined as equol producers when urinary equol level was 1.0 μM or more. The proportion of individuals with obesity (overweight and visceral obesity) and lifestyle factors were compared between equol producers and nonproducers. In addition, the association between equol and obesity was examined using logistic regression analysis with adjustment for lifestyle factors.
Results: Of the 386 participants, 106 (27.5%) women were equol producers. The proportions of women who were overweight (13.2% vs 25.7%) and had visceral obesity (6.6% vs 20.7%) were significantly lower in the equol-producing group than in the nonproducing group. Multivariable logistic regression analysis showed that equol production was significantly associated with overweight (odds ratio =0.47, 95% confidence interval: 0.25-0.88) and visceral obesity (odds ratio =0.30, 95% confidence interval: 0.13-0.68).
Conclusions: Equol is significantly associated with obesity in postmenopausal women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/GME.0000000000001761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level.
Front Nutr
October 2024
Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major public health concern that is exacerbated by the obesity pandemic. Dietary interventions have the potential to alleviate obesity-associated MASLD through variable mechanisms, including optimizing the gut microbiota. Previously, we reported that soy protein concentrate (SPC) with low or high levels of isoflavone (LIF or HIF) protected young obese Zucker rats from developing liver steatosis.
View Article and Find Full Text PDFDecreased Abundance of Genus in Individuals With Obesity and Colorectal Adenoma.
Gastro Hep Adv
March 2024
Faculty of Medicine, Department of Gastroenterology, Yamagata University, Yamagata, Japan.
Background And Aims: The increasing prevalence of obesity has significantly contributed to the global burden of colorectal cancer and the precancerous colorectal adenoma (CRA). Gut microbiota vary at each stage of colorectal carcinogenesis and participate in energy homeostasis. Elucidating gut microbiotal characteristics in obesity-related CRA may help prevent and treat colorectal tumors; however, this remains unclarified.
View Article and Find Full Text PDFThe unfolded features on the synchronized fashion of gut microbiota and Drynaria rhizome against obesity via integrated pharmacology.
Food Chem
December 2024
Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea. Electronic address:
Article Synopsis
- - The study investigates how Drynaria rhizome (DR) and gut microbiota (GM) work together to reduce obesity (OB), highlighting their mutual benefits in improving health.
- - Researchers utilized DGSTM networks, Molecular Docking Test (MDT), and Density Functional Theory (DFT) to identify crucial molecular interactions between DR and GM that contribute to weight loss.
- - Key stable compounds were identified, including NR1H3 and PPARG from DR, along with various ligands from GM, suggesting that DR-GM may effectively target the PPAR signaling pathway to combat obesity.
Urinary Equol and Equol-Predicting Microbial Genera Are Favorably Associated with Body Fat Measures among Chinese Adults.
J Nutr
September 2024
Department of Nutrition, Center for Big Data and Population Health of IHM, School of Public Health, Anhui Medical University, Hefei, Anhui, China; Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, Anhui, China; NHC Key Laboratory of study on abnormal gametes and reproductive tract, Anhui, China; Anhui Provincial Key Laboratory of Population Health and Aristogenics/Key Laboratory of Environmental Toxicology of Anhui Higher Education Institutes, Anhui Medical University, Hefei, Anhui, China. Electronic address:
Background: Many studies have investigated the intake of dietary isoflavones in relation to obesity risk, whereas the association using objective biomarkers of isoflavones, particularly equol (a gut-derived metabolite of daidzein with greater bioavailability than other isoflavones) has been less studied. In addition, the associations between equol and gut microbiota profile at the population level remain to be fully characterized.
Objectives: We aimed to identify equol-predicting microbial species and to investigate the associations of equol-predicting microbial species and urinary excretion of isoflavones including glycitein, genistein, daidzein, and equol with diverse obesity markers in free living-individuals.
The synchronized feature of and gut microbiota against T2DM, NAFLD, obesity and hypertension via integrated pharmacology.
Artif Cells Nanomed Biotechnol
December 2024
Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon, South Korea.
Type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), obesity (OB) and hypertension (HT) are categorized as metabolic disorders (MDs), which develop independently without distinct borders. Herein, we examined the gut microbiota (GM) and (SC) to confirm their therapeutic effects via integrated pharmacology. The overlapping targets from the four diseases were determined to be key protein coding genes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!